Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced
today that updated safety and efficacy data from the Phase 1 dose
escalation trial of ARV-471, a novel oral estrogen receptor
(ER)-targeting PROteolysis TArgeting Chimera (PROTAC®) protein
degrader, will be presented in a spotlight poster-discussion
session at the 2021 San Antonio Breast Cancer Symposium (SABCS) on
December 7-10, 2021. ARV-471 is being jointly developed by Arvinas
and Pfizer for the treatment of patients with locally advanced or
metastatic ER positive/human epidermal growth factor receptor 2
(HER2) negative (ER+/HER2-) breast cancer.
Presentation details are as follows:
Abstract Title: First-in-human safety and
activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in
ER+/HER2- locally advanced or metastatic breast
cancerSession Title: Spotlight Session
13Abstract Number: 2343Session
Type: Spotlight Poster-Discussion SessionSession
Date: Friday, December 10, 2021Session
Time: 7:00 a.m. - 8:30 a.m. CT
For a copy of the abstract, please visit the official SABCS
website here.
Investor Call & Webcast DetailsA conference
call and webcast will be held at 8:30 a.m. ET on Friday, December
10, 2021, with Arvinas and Pfizer Oncology executives to discuss
these data. Participants are invited to listen by dialing (844)
467-7654 (domestic) or (602) 563-8497 (international) five minutes
prior to the start of the call and providing the passcode
9122219.
Supporting materials for the conference call and webcast will be
available on Arvinas’ website at www.arvinas.com under Events +
Presentations. A replay of the webcast will be archived on the
Arvinas website following the presentation.
About ARV-471ARV-471 is an investigational
orally bioavailable PROTAC® protein degrader designed to
specifically target and degrade the estrogen receptor (ER) for the
treatment of patients with locally advanced or metastatic ER+/HER2-
breast cancer.
In preclinical studies, ARV-471 demonstrated near-complete ER
degradation in tumor cells, induced robust tumor shrinkage when
dosed as a single agent in multiple ER-driven xenograft models, and
showed superior anti-tumor activity when compared to a standard of
care agent, fulvestrant, both as a single agent and in combination
with a CDK4/6 inhibitor. In July 2021, Arvinas announced a global
collaboration with Pfizer for the co-development and
co-commercialization of ARV-471; Arvinas and Pfizer will equally
share worldwide development costs, commercialization expenses, and
profits.
About ArvinasArvinas is a clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients suffering from debilitating and life-threatening diseases
through the discovery, development, and commercialization of
therapies that degrade disease-causing proteins. Arvinas uses its
proprietary PROTAC® Discovery Engine platform to engineer
proteolysis targeting chimeras, or PROTAC® targeted protein
degraders, that are designed to harness the body’s own natural
protein disposal system to selectively and efficiently degrade and
remove disease-causing proteins. In addition to its robust
preclinical pipeline of PROTAC® protein degraders against validated
and “undruggable” targets, the company has three clinical-stage
programs: ARV-110 and ARV-766 for the treatment of men with
metastatic castrate-resistant prostate cancer; and ARV-471 for the
treatment of patients with locally advanced or metastatic ER+/HER2-
breast cancer. For more information, visit www.arvinas.com.
Arvinas Forward-Looking StatementsThis press
release contains forward-looking statements that involve
substantial risks and uncertainties, including statements regarding
the potential benefits of our arrangements with our collaborative
partnership with Pfizer, the development and regulatory status of
our product candidates, such as statements with respect to our lead
product candidates, ARV-110, ARV-471 and ARV-766 and other
candidates in our pipeline, and the timing of clinical trials and
data from those trials and plans for registration for our product
candidates, and our discovery programs that may lead to our
development of additional product candidates, the potential utility
of our technology and therapeutic potential of our product
candidates, the potential commercialization of any of our product
candidates. All statements, other than statements of historical
facts, contained in this press release, including statements
regarding our strategy, future operations, prospects, plans and
objectives of management, are forward-looking statements. The words
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,”
“might,” “plan,” “predict,” “project,” “target,” “potential,”
“will,” “would,” “could,” “should,” “continue,” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words.
We may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements, and you
should not place undue reliance on our forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements we make as a result of various risks and uncertainties,
including but not limited to: whether we and Pfizer will be able to
successfully conduct and complete clinical development for ARV-471,
whether we will be able to successfully conduct Phase 1/2 clinical
trials for ARV-110 and ARV-766, initiate and complete other
clinical trials for our product candidates, and receive results
from our clinical trials on our expected timelines, or at all and
other important factors discussed in the “Risk Factors” sections
contained in our quarterly and annual reports on file with the
Securities and Exchange Commission. The forward-looking statements
contained in this press release reflect our current views with
respect to future events, and we assume no obligation to update any
forward-looking statements except as required by applicable law.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this release.
About Pfizer OncologyAt Pfizer Oncology, we are
committed to advancing medicines wherever we believe we can make a
meaningful difference in the lives of people living with cancer.
Today, we have an industry-leading portfolio of 24 approved
innovative cancer medicines and biosimilars across more than 30
indications, including breast, genitourinary, colorectal, blood and
lung cancers, as well as melanoma.
About Pfizer: Breakthroughs That Change Patients’
LivesAt Pfizer, we apply science and our global resources
to bring therapies to people that extend and significantly improve
their lives. We strive to set the standard for quality, safety and
value in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 170 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
Pfizer Forward-Looking StatementsThe
information contained in this release is as of November 19, 2021.
Pfizer assumes no obligation to update forward-looking statements
contained in this release as the result of new information or
future events or developments.
This release contains forward-looking information about ARV-471
and a global collaboration between Pfizer and Arvinas to develop
and commercialize ARV-471, including their potential benefits, that
involves substantial risks and uncertainties that could cause
actual results to differ materially from those expressed or implied
by such statements. Risks and uncertainties include, among other
things, the uncertainties inherent in research and development,
including the ability to meet anticipated clinical endpoints,
commencement and/or completion dates for clinical trials,
regulatory submission dates, regulatory approval dates and/or
launch dates, as well as the possibility of unfavorable new
clinical data and further analyses of existing clinical data; the
risk that clinical trial data are subject to differing
interpretations and assessments by regulatory authorities; whether
regulatory authorities will be satisfied with the design of and
results from the clinical studies; whether and when any
applications may be filed for ARV-471 for any potential indications
in any jurisdictions; whether and when regulatory authorities may
approve any potential applications that may be filed for ARV-471 in
any jurisdictions, which will depend on myriad factors, including
making a determination as to whether the product’s benefits
outweigh its known risks and determination of the product’s
efficacy and, if approved, whether ARV-471 will be commercially
successful; decisions by regulatory authorities impacting labeling,
manufacturing processes, safety and/or other matters that could
affect the availability or commercial potential of ARV-471; whether
the collaboration between Pfizer and Arvinas will be successful;
uncertainties regarding the impact of COVID-19 on Pfizer’s
business, operations and financial results; and competitive
developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2020 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
Arvinas Media ContactsInvestor
Contact:Jeff Boyle, Arvinas Investor
Relations347-247-5089Jeff.Boyle@arvinas.com
Media Contact:Kirsten Owens, Arvinas
Communications203-584-0307Kirsten.Owens@arvinas.com
Pfizer Media Contacts
Investor Contact:+1 (212)
733-4848IR@pfizer.com
Media Contact:+1 (212)
733-1226PfizerMediaRelations@pfizer.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Mar 2023 to Mar 2024